Arca
Skip to content
Tools
Tools

ER+/HER2-breast cancer

Drug research and approvals for ER+/HER2-breast cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 22, 2026, 95 studies of ER+/HER2-breast cancer are recruiting on ClinicalTrials.gov, and Health Canada has authorized 11 drug trials for it since 2013.

  • Recruiting worldwide: 95
  • Trials authorized in Canada: 11
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting now

Newest posted first, of 95 recruiting on ClinicalTrials.gov ↗

Trials authorized in Canada

The 10 newest of 11; search them all in Canada trials
Aug 31, 2026A phase IIIb, single-arm, open-label, multicenter study evaluating the treatment adherence, tolerability, and patient-reported outcomes of giredestrant in…Giredestrant (GDC-9545, RO7197597) / Leuprolide / TriptorelinRocheOngoing
Aug 29, 2025A phase 3 randomized, double-blind, active-controlled study of palazestrant with ribociclib versus letrozole with ribociclib for the first-line treatment of…Palazestrant (OP-1250) / Letrozole / Ribociclib (LEE011)Olema PharmaceuticalsOngoing
Aug 6, 2025Capecitabine for targeted eradication of arising ctdna molecular residual disease in er+/HER2- negative breast cancerCapecitabineUniversity Health NetworkOngoing
Feb 14, 2024A phase I/II, open-label, multi-center trial of [177lu]lu-neob in combination with capecitabine in adult patients with grpr+, er+, HER2- metastatic breast…[177LU]LU-NEOB (AAA603) / [68GA]GA-NEOB (AAA503) / CapecitabineNovartis PharmaceuticalsOngoing
Jul 14, 2023A randomized phase II window of opportunity clinical trial of PD-1 +/- IL-4 inhibition early stage er+HER2- breast cancerCemiplimab / DupilumabOttawa Hospital Research InstitutePending
Jun 26, 2023A randomized phase 2 non-inferiority trial of (z)-endoxifen and exemestane + goserelin as neoadjuvant treatment for premenopausal women with er+/HER2- breast…Endoxifen/ Exemestane/ GoserelinAtossa Therapeutics, Inc.Pending
Nov 14, 2022A liquid-biopsy informed platform trial to evaluate treatment in CDK4/6-inhibitor resistant er+/HER2- metastatic breast cancerNiraparib / CFI-400945 / CFI-402257 / Sacituzumab govitecanCanadian Cancer Trials Group, Cancer Research Institute, Queen's UniversityOngoing
May 20, 2022A phase 1b trial of ARV-471 in combination with everolimus in patients with er+, HER2- advanced or metastatic breast cancerARV-471 / EverolimusArvinas Estrogen Receptor Inc.Pending
Nov 9, 2020A phase III randomized, double blind, placebo controlled, multicenter study evaluating the efficacy and safety of GDC-9545 combined with palbociclib compared…Giredestrant (RO7197597, GDC-9545) / Letrozole / PalbociclibRocheOngoing
May 27, 2020An open-label, randomized, multicenter study evaluating the activity of lasofoxifene relative to fulvestrant for the treatment of pre- and postmenopausal women…LasofoxifeneSermonix PharmaceuticalsOngoing

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.